Close Menu

NEW YORK – Roche announced Tuesday that its Cobas HPV test for human papillomavirus was approved by the US Food and Drug Administration for use with its high-throughput Cobas 6800/8800 systems.

The Cobas HPV test was previously approved for use with the Cobas 4800 system in 2014. It detects the presence of the DNA of HPV genotypes 16 and 18 in cervical samples, which are responsible for 70 percent of all cervical cancers, according to Roche. It also reports the 12 other high-risk HPV types as a combined result from one sample.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.